** Shares of WuXi XDC Cayman Inc 2268.HK, a Chinese antibody drug conjugates research, development and manufacturing services provider, jump 14.5% to HK$56.55, their highest level since debut in November 2023
** Stock marks its biggest intraday pct gain since July 31, 2024 and on track to snap three straight sessions of losses, if current trend continues
** Top pct gainer in healthcare index .HSCIH, which is up 1.2%
** Co expects H1 net profit to increase more than 50% y/y, with revenue up over 60% y/y, due to growth of downstream demand in antibody drug conjugate and broader bioconjugate industry, among others
** Hang Seng Biotech Index .HSHKBIO rises 1.1%, benchmark Hang Seng Index .HSI climbs 0.6%
** YTD, stock up 81.4%
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。